Imeglimin: Finding a Place in Modern Diabetes Pharmacotherapeutics

Authors

  • Sanjay Kalra Dept. of Endocrinology, Bharti Hospital, Karnal, Haryana, India; University Center for Research & Development, Chandigarh University, Mohali, Punjab, India
  • Saptarshi Bhattacharya Dept. of Endocrinology, Apollo Indraprastha Hospital, New Delhi, India
  • Shehla Shaikh Dept. of Endocrinology, Saifee Hospital, Mumbai, Maharashtra, India

Keywords:

Gluconeogenesis, imeglimin, oxidative phosphorylation inhibitor, mitochondria, pharmacotherapeutics, type 2 diabetes mellitus

Abstract

Type 2 diabetes mellitus (T2DM) is a multifactorial disease. Newer facets of its causation, clinical course, complications and therapy are being unraveled regularly. This editorial describes imeglimin, a first-of-class oxidative phosphorylation inhibitor, that has been approved for T2DM in Japan and India.

Additional Files

Published

2022-07-01

Issue

Vol. 23 No. 3 (2022)

Section

Clinical Perspectives

License

Copyright (c) 2022 Sanjay Kalra

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Similar Articles

1-10 of 66

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>